The Challenge of Sticking With It
GLP-1 agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed weight management. Yet, real-world data shows that a significant number of patients do not continue treatment long-term. Studies indicate that discontinuation
rates can be as high as 50% to 75% within the first year. While factors like high cost and insurance battles are well-documented reasons for stopping, a growing body of research emphasizes the role of treatment-related side effects, which can become severe enough to be considered an illness that drives patients to quit.
Gastrointestinal Issues are the Main Culprit
The most common reason for medically-driven discontinuation is persistent gastrointestinal (GI) distress. These drugs work by slowing down how quickly the stomach empties, which helps control appetite but can also cause a cascade of uncomfortable symptoms. Nausea is the most frequently reported side effect, affecting up to 50% of patients, particularly when starting the medication or increasing the dose. Other common issues include vomiting, diarrhea, constipation, and abdominal pain. While these symptoms are often mild to moderate and transient for many, for others they are severe and persistent, significantly impacting their quality of life and leading them to abandon the treatment.
When Side Effects Become Intolerable
For a subset of patients, these GI issues are not just a minor inconvenience; they become a chronic problem. Doctors report that while side effects often diminish as the body adjusts, they can lead to complications like dehydration or nutritional deficiencies if they are severe and unmanaged. Studies show that patients who stop treatment due to side effects tend to do so early, often within the first three months. This highlights a critical window where patient support and symptom management are essential. If symptoms like severe vomiting, intense abdominal pain, or an inability to keep fluids down occur, it is a sign that the medication may be intolerable for that individual.
Managing the Journey
Experts stress that managing these side effects is key to improving long-term adherence. Physicians are increasingly focused on proactive strategies, including starting patients on the lowest possible dose and titrating upwards very slowly. Patients are often advised to make dietary changes, such as eating smaller, more frequent meals and avoiding high-fat or greasy foods that can worsen nausea. Staying hydrated and communicating openly with a healthcare provider about the severity of side effects is crucial. In some cases, doctors may prescribe anti-nausea medications to help patients get through the initial adjustment period.
The Consequences of Stopping
Stopping GLP-1 medications is not without consequences. Because obesity is a chronic disease, the effects of the medication typically only last as long as it is being taken. Studies show that the vast majority of patients regain the weight they lost within a year of discontinuing the drug. Beyond weight regain, patients with type 2 diabetes who stop the medication can experience a rise in blood sugar levels and may face an increased risk of cardiovascular events like heart attack or stroke. This underscores the importance of viewing these medications as long-term treatments rather than short-term fixes and finding a sustainable way for patients to continue therapy.
















